Clinical trial · Observational
Active Surveillance of the Small Renal Mass
Active Surveillance of the Small Renal Mass: An Integrated Biomarker Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Active surveillance in kidney cancer involves closely observing the tumor with periodic imaging studies rather than immediately proceeding to an invasive treatment. This does not mean that the tumor is ignored or that future treatment is not necessary, rather it means the tumor does not require treatment at this time. On active surveillance, a tumor is closely monitored without treatment, however if the tumor changes and reaches a predefined threshold that your physician no longer considers safe, your physician will strongly encourage treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Renal Mass, Kidney Cancer | Kidney Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Small clear cell renal tumors (Wild Type)
- description
- No specific chromatin remodeling gene (CRG) alteration
- label
- Small clear cell renal tumors (Mutant)
- description
- Specific chromatin remodeling gene (CRG) alteration
Primary outcomes (1)
- measure
- Tumor growth rate
- timeFrame
- 36 months
- description
- Tumor growth rate is being measured in centimeters/year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Life expectancy \>3 years (by physician estimate) * Measurable, solid renal neoplasm, 1.0 -2.7 cm in size and visible on ultrasound * Clear cell renal cell carcinoma histology * Renal tumor diagnosed within 6 months * Recent biopsy (\<6 weeks) performed, if performed at an outside institution, there must be sufficient material for biomarker analysis * No evidence of vascular invasion or regional nodal/distant disease * Renal tumor that is able to be managed with upfront surgery * Adequate organ function (Hemoglobin \> 9, Absolute neutrophil count (ANC) ≥ 1500/μL Platelets ≥ 100,000/μL, AST and ALT ≤3.0 upper limit of normal (ULN), total bilirubin ≤ ULN, eGFR ≥ 30 * Good Performance status (ECOG ≤2) * Understanding and willingness to provide consent Exclusion Criteria: * History of a hereditary renal cancer syndrome * Tumor \>2.7 cm, stages T1b-T4 * Life expectancy \<3 years * Presence of an active, untreated, metastatic non-renal malignancy * Uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction within 6 months that would predispose to immediate surgical therapy * Medical contraindication to upfront surgical management of renal mass * History of bleeding diathesis or recent bleeding episode that would prevent surgical resection * Unwillingness to undergo monitoring and imaging studies
References
Publications (0)
Data not yet available